/NAUT

NAUT Stock - Nautilus Biotechnology, Inc.

Q: What is the analyst price target for NAUT?

Analyst price target information is not currently available for NAUT.

Q: What is NAUT's market cap?

Market capitalization information is not currently available for NAUT.

Healthcare|Biotechnology|NASDAQ

$1.94+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+28.9%upside

Target: $2.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NAUT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.39

52W High$2.54

52W Low$0.62

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-6,353,000	$-5,705,000	$-3,416,000	$-2,842,000	$-2,346,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-81,476,000	$-76,152,000	$-63,618,000	$-50,498,000	$-15,744,000
Net Income	$-70,780,000	$-63,675,000	$-57,924,000	$-50,315,000	$-15,619,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.56	$-0.51	$-0.46	$-0.60	$-0.47

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

33%

Hold / Neutral

33%

Sell / Underperform

33%

Analyst Consensus🔴 Bearish

1 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 84.7% Upside

Now

Low

Average

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 5th 2024	Goldman	Downgrade	Sell	$1.75
June 27th 2024	Guggenheim	Initiation	Buy	$6
June 3rd 2024	Jefferies	Resumed	Hold	$3

Earnings History & Surprises

NAUT

Beat Rate

89%

Last 18 quarters

Avg Surprise

+10.2%

EPS vs Estimate

Beats / Misses

16/2

Last 12 quarters

Latest EPS

$-0.11

Q4 2025

EPS Surprise History

Q1 24

+12.5%

$-0.14vs$-0.16

Q2 24

+6.3%

$-0.15vs$-0.16

Q3 24

+12.5%

$-0.14vs$-0.16

Q4 24

+23.5%

$-0.13vs$-0.17

Q1 25

+12.5%

$-0.14vs$-0.16

Q2 25

+7.1%

$-0.13vs$-0.14

Q3 25

+22.6%

$-0.12vs$-0.15

Q4 25

+26.7%

$-0.11vs$-0.15

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 27, 2026	—	—	—	—
Q1 2026	Feb 25, 2026	—	—	—	—
Q4 2025	Oct 27, 2025	$-0.15	$-0.11	+26.7%	✓ BEAT
Q3 2025	Jul 31, 2025	$-0.15	$-0.12	+22.6%	✓ BEAT
Q2 2025	Apr 29, 2025	$-0.14	$-0.13	+7.1%	✓ BEAT
Q1 2025	Feb 26, 2025	$-0.16	$-0.14	+12.5%	✓ BEAT
Q4 2024	Oct 29, 2024	$-0.17	$-0.13	+23.5%	✓ BEAT
Q3 2024	Jul 30, 2024	$-0.16	$-0.14	+12.5%	✓ BEAT
Q2 2024	Apr 30, 2024	$-0.16	$-0.15	+6.3%	✓ BEAT
Q1 2024	Feb 28, 2024	$-0.16	$-0.14	+12.5%	✓ BEAT
Q4 2023	Oct 31, 2023	$-0.18	$-0.13	+27.8%	✓ BEAT
Q3 2023	Aug 2, 2023	$-0.17	$-0.13	+23.5%	✓ BEAT
Q2 2023	May 2, 2023	$-0.16	$-0.12	+25.0%	✓ BEAT
Q1 2023	Feb 23, 2023	$-0.15	$-0.11	+26.7%	✓ BEAT
Q4 2022	Nov 1, 2022	$-0.14	$-0.11	+21.4%	✓ BEAT
Q3 2022	Aug 2, 2022	$-0.17	$-0.12	+29.4%	✓ BEAT
Q2 2022	May 3, 2022	$-0.15	$-0.13	+13.3%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.15	$-0.13	+13.3%	✓ BEAT
Q4 2021	Nov 2, 2021	$-0.11	$-0.12	-9.1%	✗ MISS
Q3 2021	Aug 10, 2021	$-0.09	$-0.19	-111.1%	✗ MISS

Frequently Asked Questions about NAUT

What is NAUT's current stock price?

Nautilus Biotechnology, Inc. (NAUT) is currently trading at $1.94 per share. The stock has moved +0.00% today.

What is the analyst price target for NAUT?

The average analyst price target for NAUT is $2.50, based on 1 analyst.

What sector is Nautilus Biotechnology, Inc. in?

Nautilus Biotechnology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is NAUT's market cap?

Nautilus Biotechnology, Inc. has a market capitalization of $0.25 billion, making it a small-cap company.

Does NAUT pay dividends?

No, Nautilus Biotechnology, Inc. does not currently pay a dividend to shareholders.